(RTTNews) – U.S. President Donald Trump plans to push the candidate for the coronavirus vaccine from British drug manufacturer AstraZeneca to make it available in the United States ahead of the November presidential election, the Financial Times reported.
The report comes at a time when the U.S. Food and Drug Administration It has issued an emergency use authorization or an US for experimental convalescent plasma to treat COVID-19 in hospitalized patients. The blood of others who have recovered from the disease is called convalescent plasma.
Coronavirus has inflamed more than 5.7 million people in the United States, while the death toll has risen to more than 176,000, according to Johns Hopkins University.
AstraZeneca will present the coronavirus vaccine, AZD1222, in partnership with the University of Oxford. The company earned more than $1 billion from the U.S. Advanced Biomedical Research and Development Authority. To expand the vaccine.
Under the agreement, AstraZeneca would be engaged in the development, manufacture and overall distribution of the vaccine.
In July 2020, the provisional effects of the current Phase I/II COV001 trial, led by the University of Oxford, were published in The Lancet. Intermediate effects showed that AZD1222 tolerated and generated physically powerful immune responses opposed to SARS-CoV-2 in all participants evaluated.
The vaccine is lately in complex Phase II/III trials that are recently being conducted in the UK, Brazil and South Africa, and is expected to begin in the United States, Japan and Russia. Results are expected by the end of the year.